Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma
- PMID: 6173399
- PMCID: PMC370996
- DOI: 10.1172/jci110470
Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma
Abstract
Although Cl-inhibitor (Cl-INH) and alpha(2)-macroglobulin (alpha(2)M) have been reported as the major inhibitors of plasma kallikrein in normal plasma, there is little quantitative support for this conclusion. Thus, we studied the inactivation of purified kallikrein in normal plasma, as well as in plasma congenitally deficient in Cl-INH, or artificially depleted of alpha(2)M by chemical modification of the inhibitor with methylamine. Under pseudo-first-order conditions, the inactivation rate constant of kallikrein in normal plasma was 0.60 min(-1). This rate constant was reduced to 0.35, 0.30, and 0.06 min(-1), in plasma deficient respectively in Cl-INH, alpha(2)M, or both inhibitors. Thus Cl-INH (42%) and alpha(2)M (50%) were found to be the major inhibitors of kallikrein in normal plasma. Moreover all the other protease inhibitors present in normal plasma contributed only for 8% to the inactivation of the enzyme. To confirm these kinetic results, (125)I-kallikrein (M(r) 85,000) was completely inactivated by various plasma samples, and the resulting mixtures were analyzed by gel filtration on Sepharose 6B CL for the appearance of (125)I-kallikrein-inhibitor complexes. After inactivation by normal plasma, 52% of the active enzyme were found to form a complex (M(r) 370,000) with Cl-INH, while 48% formed a complex (M(r) 850,000) with alpha(2)M. After inactivation by Cl-INH-deficient plasma, >90% of the active (125)I-kallikrein was associated with alpha(2)M. A similar proportion of the label was associated with Cl-INH in plasma deficient in alpha(2)M. After inactivation by plasma deficient in both Cl-INH and alpha(2)M, (125)I-kallikrein was found to form a complex of M(r) 185,000. This latter complex, which may involve antithrombin III, alpha(1)-protease inhibitor, and/or alpha(1)-plasmin inhibitor, was not detectable in appreciable concentrations in the presence of either Cl-INH or alpha(2)M, even after the addition of heparin (2 U/ml). These observations demonstrate that Cl-INH and alpha(2)M are the only significant inhibitors of kallikrein in normal plasma confirming previous predictions based on experiments in purified systems. Moreover, in the absence of either Cl-INH or alpha(2)M, the inactivation of kallikrein becomes almost entirely dependent on the other major inhibitor.
Similar articles
-
Inactivation of kallikrein in human plasma.J Clin Invest. 1983 Jan;71(1):149-58. doi: 10.1172/jci110743. J Clin Invest. 1983. PMID: 6184384 Free PMC article.
-
New and rapid functional assay for C1 inhibitor in human plasma.Blood. 1982 Apr;59(4):719-24. Blood. 1982. PMID: 6174161
-
High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein.Biochemistry. 1993 Nov 16;32(45):12136-47. doi: 10.1021/bi00096a026. Biochemistry. 1993. PMID: 7692967
-
Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.Adv Immunol. 2014;121:41-89. doi: 10.1016/B978-0-12-800100-4.00002-7. Adv Immunol. 2014. PMID: 24388213 Review.
-
Structure and function of C1 inhibitor.Behring Inst Mitt. 1989 Jul;(84):142-50. Behring Inst Mitt. 1989. PMID: 2679529 Review.
Cited by
-
N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the c1 inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A.Infect Immun. 2005 Aug;73(8):4478-87. doi: 10.1128/IAI.73.8.4478-4487.2005. Infect Immun. 2005. PMID: 16040958 Free PMC article.
-
Human plasma kallikrein: roles in coagulation, fibrinolysis, inflammation pathways, and beyond.Front Physiol. 2023 Aug 30;14:1188816. doi: 10.3389/fphys.2023.1188816. eCollection 2023. Front Physiol. 2023. PMID: 37711466 Free PMC article. Review.
-
C1 inhibitor deficiency enhances contact pathway-mediated activation of coagulation and venous thrombosis.Blood. 2023 May 11;141(19):2390-2401. doi: 10.1182/blood.2022018849. Blood. 2023. PMID: 36701760 Free PMC article.
-
Heat-Inactivation of Human Serum Destroys C1 Inhibitor, Pro-motes Immune Complex Formation, and Improves Human T Cell Function.Int J Mol Sci. 2021 Mar 5;22(5):2646. doi: 10.3390/ijms22052646. Int J Mol Sci. 2021. PMID: 33808005 Free PMC article.
-
Prekallikrein activation in human, bovine, and rabbit plasmas: presence of an inhibitor in bovine plasma.Inflammation. 1992 Jun;16(3):205-13. doi: 10.1007/BF00918810. Inflammation. 1992. PMID: 1500097
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous